TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Elective open anatomic lung resections: segmentectomy, lobectomy, bi-lobectomy~2. Colorectal surgery for non-metastatic disease (including right, transverse, left, sigmoid, subtotal, total, and hemicolectomy)~3. Primary or secondary lung cancer~4. At least 18 years of age with~5. HbA1c 5.7- 6.5 %~6. Not receiving any kind of glucose lowering medication.~Exclusion Criteria:~1. Already diagnosed with diabetes (Hb A1c \> 6.5%)~2. Are pre-diabetic receiving glucose lowering intervention ( any glucose lowering medication)~3. Have renal or liver dysfunction (serum creatinine above 124 micromol/L in women and 133 micromol/L in men, bilirubin \>50 micromol/L)~4. will undergo extended resection of adjacent organs, chest wall resections, bronchoplasty, non-anatomic lung resections~5. Will undergo Pneumonectomy~6. Non-elective operations~7. Have mental conditions (e.g. dementia, disabling orthopedic and neuromuscular disease, psychosis),~8. Have cardiac abnormalities, severe end-organ disease such as cardiac failure (New York Heart Association classes III-IV), Chronic obstructive pulmonary disease(COPD), sepsis, morbid obesity (BMI \>40 kg/m2), anemia (hematocrit \< 30 %, hemoglobin \<100g/L albumin \< 25mg/dl)~9. Have received steroids for longer than 30 days~10. Have poor English or French comprehension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered exactly in the similar way to Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18 to 65 years of age, inclusive~* Inactive CHB with documented HBsAg positivity for at least 12 months before Day 1~* qHBsAg ≥ 10 IU/mL but ≤ 100 IU/mL in the 12 months prior to screening~* HBV DNA ≥ 10 IU/mL at screening~* AST, ALT, INR, albumin, total bilirubin (excluding patients with Gilbert Syndrome) and direct bilirubin within normal limits at screening~Exclusion Criteria:~* Positive hepatitis B e antigen (HBeAg) at screening~* History of a hepatitis B flare or 1-log increase in HBV DNA or HBsAg in the prior 12 months~* Undetectable HBV DNA at screening~* Fibroscan \> 8.5 kPA at screening, or history of hepatic fibrosis or cirrhosis (NB, a Fibroscan is not required if an examination is performed within 12 months or a liver biopsy was performed within 2 years before Screening and no fibrosis \[F1 or greater\] was identified).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HepTcell (Type: EXPERIMENTAL): Dose administered at intervals of 4 weeks for 6 doses
- Placebo (Type: PLACEBO_COMPARATOR): Dose administered at intervals of 4 weeks for 6 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: OPTIMA-TBI Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals presenting to the emergency department (ED) within 24 hours of injury, who meet the American Congress of Rehabilitation Medicine (ACRM)'s definition of having mild traumatic brain injury (mTBI) will be eligible~* The ACRM defines mTBI as a traumatically-induced physiological disruption of brain function as a consequence of the head being struck, striking an object, or undergoing an acceleration/deceleration movement without direct external head trauma and resulting in at least one of the following:~* any period of loss of consciousness (LOC)~* any loss of memory for events immediately before or after the injury~* any alteration in mental state at the time of the injury (eg, feeling dazed, disoriented, or confused)~* focal neurological deficit(s) that may or may not be transient~Exclusion Criteria:~* GCS\<13 at any time during ED stay.~* Significant polytrauma including: bony fracture or solid organ injury~* Study medication cannot be administered within 24 hours of injury~* Patient cannot be relied on to complete follow-up (i.e. no reliable telephone number, substance dependence, homeless)~* Cannot communicate in English~* Take an anticoagulant (coumadin or a novel oral anticoagulant) daily~* Age less than 18 years or greater than 65 years~* Patients already taking fish oil supplements daily~* History of cognitive impairment~* Allergic to fish/fish oil~* Pregnant women (self-reported)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3 Polyunsaturated Fatty Acid Treatment Arm (Type: EXPERIMENTAL): Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Participants randomized to this study arm will receive placebo drug for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-operative Analgesia in Elective, Soft-tissue Hand Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18~* Male or Female (non-pregnant)~* Elective, soft tissue hand surgery indicated based on diagnosis made by either clinical exam or diagnostic studies (ie nerve conduction study, EMG) or a combination of the two (carpal tunnel release, trigger finger release, first dorsal compartment release, ganglion cyst excision, second extensor compartment release)~* Subjects are capable of giving informed consent~Exclusion Criteria:~* Allergy to study medication~* Any pre-existing pain condition requiring analgesia~* Fibromyalgia~* Recent upper gastrointestinal bleeding~* Coagulopathy (primary or medication-related)~* Renal impairment~* Liver disease~* Pregnancy~* Patients who consent to the study but require unexpected admission, including those requiring admission resulting from operative complications, will be excluded before randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetaminophen/Ibuprofen (AIBU) Group (Type: ACTIVE_COMPARATOR): Acetaminophen 500 mg and Ibuprofen 400 mg
- Acetaminophen/Hydrocodone (AH) Group (Type: ACTIVE_COMPARATOR): Acetaminophen 325 mg and Hydrocodone 5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Status Monitoring in Implantable Cardiac Defibrillator (ICD) Patients by Physiological Diagnosis (PhD) Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient eligible for implantation of an ICD or a CRT-D device according to current available guidelines.~2. Documented chronic HF (NYHA Class II to IV) at the time of enrollment~3. Scheduled for implant of a PARADYM ICD / CRT-D or implanted within the previous month~4. Signed and dated informed consent~Exclusion Criteria:~1. Any contraindication for ICD therapy~2. Abdominal implantation site~3. Acute myocarditis~4. Unstable coronary symptoms (unstable angina or myocardial infarction) within the last month~5. Planned heart transplant~6. Mechanical tricuspid valve~7. Unable to perform the 6 minute Walking Test at time of enrollment~8. Already included in another clinical study~9. Life expectancy less than 13 months~10. Inability to understand the purpose of the study or refusal to cooperate~11. Inability or refusal to provide informed consent~12. Under guardianship~13. Age of less than 18 years~14. Pregnancy (Women of childbearing potential should have a negative pregnancy test prior to enrollment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Atrial Tissue Banking: Atrial Tissue Obtained From Patients Undergoing Heart Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18+ years of age~* Referred for heart surgery for standard indication~* Competent to give informed consent~Exclusion Criteria:~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women~* Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450)~Exclusion Criteria:~* Active or draining fistula present at screening~* Lactating and/or pregnant female subjects~* A history of any health condition that could potentially interfere with the disease and/or the treatment~* A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product~* Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study~* History of drug or alcohol abuse in the prior year~* Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 400 mg (Type: EXPERIMENTAL): Certolizumab pegol 400 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 18 years~2. Able to give informed consent~3. New diagnosis of AML, other than APL or poor-risk AML, as defined in section 3.2~Exclusion criteria:~1. Has already had a bone marrow biopsy and aspirate to assess remission status after induction therapy~2. Any debilitating medical or psychiatric illness that would preclude ability to give informed consent or receive optimal treatment and follow-up~3. Pregnancy: Women of childbearing potential who are β- HCG+

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- No Leukemia Stem Cells - Consolidation (Type: EXPERIMENTAL): Without LSC, standard cytarabine consolidation
- Leukemia Stem Cells - Consolidation (Type: EXPERIMENTAL): LSC present, randomized to cytarabine consolidation
- Leukemia Stem Cells - Transplant (Type: EXPERIMENTAL): LSC present, randomized to allogeneic transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give informed consent~* Presence of an ileostomy \> 2 months~* Weight stable\* for \>2 months (i.e. no greater than 7% change in body weight the last 2 months)~Exclusion Criteria:~* Crohn's Disease~* Steroid use in the last 3 months~* Documented/known diagnosis of type 1 diabetes or type 2 diabetes, chronic liver disease, chronic kidney disease, heart failure, cardiac dysrhythmias, or familial hypercholesterolemia~* Current use of any over-the-counter or prescription oral bile salt~* Currently pregnant~* Current use of medications that are known to interact with Ursodiol~* Current or former smoker within the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ursodeoxycholic Acid/Placebos (Type: ACTIVE_COMPARATOR): During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
- Placebos/Ursodeoxycholic Acid (Type: ACTIVE_COMPARATOR): Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Astaxanthin for Management of Inflammation in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Radiographic evidence of advanced knee osteoarthritis~* Knee pain~* Scheduled to undergo a total knee replacement~Exclusion Criteria:~* \< 18 years of age~* Unable to provide written consent~* Known allergy to fish or astaxanthin~* Pregnant and/or breastfeeding~* Received a corticosteroid injection within 3 months of initiating treatment with astaxanthin or placebo~* Currently taking immunosuppressants~* Patients with known autoimmune etiology for arthritis (e.g. Rheumatoid or Psoriatic arthritis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control: Placebo Group (Type: PLACEBO_COMPARATOR): Patients will receive a 6 week daily oral supply of placebo, identical in appearance to the astaxanthin supplement.
- Experimental: Astaxanthin Supplementation Group (Type: ACTIVE_COMPARATOR): Patients will receive a 6 week daily oral supply of 12 mg astaxanthin supplement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age at inclusion 3-16 years~* male or female patients~* recipient of first or second renal transplant~* graft age \> 24 months~* last acute rejection episode \> 6 months ago~* Immune suppression comedication Mycophenolatmofetil (MMF) in a dose range of 1200 +/- 200 mg/m² BSA/d within at least 6 months or minimal MPA-AUC ≥ 45 mg x h/l. If MPA-AUC \< 45 mg x h/l adjustment of dosage with re-screening in ≥ 4 weeks is possible.~* Application of CSA in stable dosing within the last 3 months before study inclusion and CSA-C2-level \> 500 ng/ml. If CSA-C2-level \< 500 ng/ml adjustment of dosage with re-screening in ≥ 4 weeks is possible.~* steroid-free immunosuppression for at least 6 months before enrollment~* biopsy of the renal graft without any signs of acute rejection (def. according to BANFF classification), within 3 months before enrollment~* written informed consent of parents/legal guardians and, if applicable, patient's consent~Exclusion Criteria:~* glomerular filtration rate \< 40 ml/min/1.73 m2 BSA (acc. to Schwartz' formula) at time of enrollment~* \> 2 episodes of acute graft rejection within 12 months prior to enrollment~* condition after steroid-resistant graft rejection~* actual participation in another clinical trial~* Recurrence of primary renal disease in the graft~* proven infection with EBV and/ or CMV and antiviral therapy within 3 months prior to enrollment~* proven infection with polyoma virus within 3 months prior to enrolment~* pregnant or nursing women~* hemoglobin \< 8 g/dl at screening visit~* non-treated arterial hypertension~* uncontrolled infectious disease~* history of malignancy of any organ system, treated or non-treated

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
- B (Type: NO_INTERVENTION): Standard CSA-dosing without reduction. Therapy control by C2-monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trental for the Treatment of Vertigo/Dizziness/Imbalance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults 40 years and older~2. English as primary language~3. Diagnosis of multisensory losses, presbystasis, bilateral vestibulopathy, central vascular insufficiency, small vessel circulatory disease, generalized imbalance, and idiopathic peripheral vertigo scoring at least 16 on the Dizziness Handicap Inventory~4. Willingness to complete surveys and take medication as prescribed~Exclusion Criteria:~1. Diagnosis of the following: benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine with headache, intracranial mass, perilymphatic fistula, or multiple sclerosis~2. history of cholesteatoma~3. Prior ear surgery other than myringotomy and tube placement~4. Prior radiation to head or neck~5. previous use of vestibulotoxic medications where the enrolling provider determines the drug exposure to be the cause of imbalance~6. Use of blood thinning medications~7. intolerance/allergy to pentoxifylline or methylxanthines, as well as recent cerebral or retinal hemorrhage (past 3 months)~8. Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Patients will take placebo 3 times per day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal failure, stage 3 or worse~* Undergoing endovascular procedure with an isotonic, non ionized contrast agent~* Life expectancy at least 4 weeks from date of registration~* Platelets greater than or equal to 100,000/mm3~* Systolic pressure of greater than 90 mm Hg~* No contraindications to N-Ac or contrast agent~* Not at risk for general anesthesia~Exclusion Criteria:~* Acute renal failure~* Undergoing dialysis~* Decompensate cardiac failure~* Pregnant or nursing~* History of clinically significant reactive airway disease~* Receiving non-steroidal anti-inflammatory agent within 24 hours of study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1, IV NAC (Type: EXPERIMENTAL): N-acetylcysteine administered intravenously
- 2, IA NAC (Type: EXPERIMENTAL): N-acetylcysteine administered intra-arterial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues